Clinical Efficacy of <italic style="font-style: italic">Shenyu Guanchang Formula</italic> （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research

LIU Yijing; ZHANG Mengyuan; SHEN Hong; ZHU Lei

doi:10.13288/j.11-2166/r.2026.08.013

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Shenyu Guanchang Formula （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research

更新时间：2026-04-16

- Clinical Efficacy of Shenyu Guanchang Formula （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research
  增强出版
- Journal of Traditional Chinese Medicine Vol. 67, Issue 8, Pages: 881-887(2026)
- 作者机构：
  
  江苏省中医院/南京中医药大学附属医院，江苏省南京市秦淮区汉中路155号，210029
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2026.08.013
  CLC：
- Received：30 September 2025，
  
  Revised：2026-02-06，
  
  Accepted：13 January 2026，
  
  Published：17 April 2026
- 稿件说明：
移动端阅览
刘怡婧,张梦媛,沈洪等.参榆灌肠方联合美沙拉嗪缓释颗粒治疗左半结肠型溃疡性结肠炎大肠湿热证患者的临床疗效及网络药理学研究[J].中医杂志,2026,67(08):881-887.

LIU Yijing,ZHANG Mengyuan,SHEN Hong,et al.Clinical Efficacy of Shenyu Guanchang Formula （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research[J].Journal of Traditional Chinese Medicine,2026,67(08):881-887.
刘怡婧,张梦媛,沈洪等.参榆灌肠方联合美沙拉嗪缓释颗粒治疗左半结肠型溃疡性结肠炎大肠湿热证患者的临床疗效及网络药理学研究[J].中医杂志,2026,67(08):881-887. DOI： 10.13288/j.11-2166/r.2026.08.013.

LIU Yijing,ZHANG Mengyuan,SHEN Hong,et al.Clinical Efficacy of Shenyu Guanchang Formula （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research[J].Journal of Traditional Chinese Medicine,2026,67(08):881-887. DOI： 10.13288/j.11-2166/r.2026.08.013.

摘要

目的

评估在口服美沙拉嗪缓释颗粒基础上应用参榆灌肠方灌肠治疗左半结肠型溃疡性结肠炎（UC）大肠湿热证患者的临床疗效，并应用网络药理学方法探讨其可能作用机制。

方法

采用前瞻性队列研究，纳入轻中度活动期左半结肠型大肠湿热证UC患者，根据患者意愿分为观察组和对照组各30例。两组均予美沙拉嗪缓释颗粒口服，每日3 g；观察组联合参榆灌肠方灌肠（每日1次）；对照组联合美沙拉嗪栓塞肛（每日1枚）；两组疗程均为8周。主要疗效指标为临床缓解率，次要疗效指标包括部分改良Mayo评分、中医单项症状评分、炎症性肠病生存质量量表（IBDQ）评分和炎症性肠病残疾指数（IBD-DI）评分，并记录不良事件及不良反应的发生情况。采用网络药理学方法分析参榆灌肠方活性成分和关键靶点，探究其潜在作用机制，并应用分子对接预测参榆灌肠方核心活性成分与关键靶点间结合活性。

结果

治疗8周后，观察组临床缓解率为86.7%（26/30），对照组76.7%（23/30），两组差异无统计学意义（

＞0.05）。观察组治疗后部分改良Mayo评分、脓血便症状评分及IBD-DI评分均低于对照组（

＜0.05）。两组患者治疗期间均未出现严重不良事件和不良反应。结合网络药理学筛选得到参榆灌肠方治疗UC的核心药物活性成分前5位为槲皮素、山柰酚、木犀草素、β-谷甾醇、豆甾醇，关键蛋白靶点前5位为肿瘤蛋白p53（TP53）、白细胞介素-6（IL-6）、丝氨酸/苏氨酸激酶1（AKT1）、白细胞介素-1β（IL-1β）、表皮生长因子受体（EGFR）。

结论

在口服美沙拉嗪基础上应用参榆灌肠方灌肠能够较好地改善左半结肠型UC大肠湿热证患者的临床症状，提高患者生存质量，降低残疾指数，且安全性较好。参榆灌肠方治疗UC可能与癌症通路和炎症通路相关，槲皮素、山柰酚等可能是其治疗UC的核心活性化合物。

Abstract

Objective

To evaluate the clinical efficacy of

Shenyu Guanchang Formula

（参榆灌肠方， SGF） enema combined with oral mesalazine in the treatment of left-sided ulcerative colitis （UC） with large intestine damp-heat syndrome， and to explore its possible mechanism of action through network pharmacology.

Methods

In a prospective cohort design， a total of 60 patients diagnosed with left-sided UC in the mild-moderate active stage were enrolled and were divided into an observation group and a control group according to patients' willingness， with 30 participants in each arm. Both groups received oral mesalazine sustained-release granules at 3 g daily. The observation group was additionally treated with SGF by enema once daily， while the control group received mesalazine suppositories per rectum one suppository daily. The treatment course lasted 8 weeks. The primary efficacy endpoint was the clinical remission rate， and the secondary endpoints included the Mayo score， the scores of individual symptoms in traditional Chinese medicine （TCM）， the inflammatory bowel disease questionnaire （IBDQ） score， and the inflammatory bowel disease disability index （IBD-DI） score. Adverse events and adverse reactions were recorded throughout the study. Network pharmaco-logy was used to analyze the active components and key targets of SGF， exploring its potential mechanisms of action， and applying molecular docking to predict the binding activity between the core active components of SGF and the key targets.

Results

After 8 weeks of treatment， the clinical remission rate was 86.7% （26/30） in the observation group， higher than 76.7% （23/30） in the control group， while the difference was not significant （

＞0. 05）. The observation group had lower partial modified Mayo scores， bloody stool symptom score， and IBD-DI scores than the control group （

＜0.05）. No seve

re adverse events or reactions were observed during the treatment of both groups. Based on network pharmacology screening， the top five core active components of SGF for UC treatment were quercetin， kaempferol， luteolin， β-sitosterol， and stigmasterol； and the top five key protein targets were tumor protein p53 （TP53）， interleukin-6 （IL-6）， serine/ threonine kinase 1 （AKT1）， interleukin-1β （IL-1β）， and epidermal growth factor receptor （EGFR）.

Conclusion

SGF enema combined with oral mesalazine can effectively alleviate clinical symptoms， improve quality of life and reduce the disability index in left-sided UC patients with large intestine damp-heat syndrome， with favorable safety. SGF may exert its function through cancer pathways and inflammatory pathways， and quercetin， kaempferol， and other compounds may be the core active ingredients for treating UC.

关键词

Keywords

references

LAMB C A ， KENNEDY N A ， RAINE T ， et al . British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults ［J］. Gut ， 2019 ， 68 （ Suppl 3 ）： s1 - s106 .

MOLODECKY N A ， SOON I S ， RABI D M ， et al . Increasing incidence and prevalence of the inflammatory bowel diseases with time， based on systematic review ［J］. Gastroenterology ， 2012 ， 142 （ 1 ）： 46 - 54 .

RODA G ， NARULA N ， PINOTTI R ， et al . Systematic review with meta-analysis： proximal disease extension in limited ulcerative colitis ［J］. Aliment Pharmacol Ther ， 2017 ， 45 （ 12 ）： 1481 - 1492 .

COHEN R D ， WEISSHOF R . A comprehensive review of topi-cal therapies for distal ulcerative colitis ［J］. Gastroenterol Hepatol ， 2020 ， 16 （ 1 ）： 21 - 27 .

刘琼，成哲，陈广 . 溃疡性结肠炎中医治疗进展［J］. 中国中医基础医学杂志， 2021 ， 27 （ 7 ）： 1191 - 1194 .

中华医学会消化病学分会炎症性肠病学组 . 炎症性肠病诊断与治疗的共识意见（2018年，北京）［J］ . 中华消化杂志， 2018 ， 38 （ 5 ）： 292 - 311 .

中华中医药学会脾胃病分会 . 溃疡性结肠炎中医诊疗专家共识意见（2017）［J］. 中华中医药杂志， 2017 ， 32 （ 8 ）： 3585 - 3589 .

中国中西医结合学会消化系统疾病专业委员会 . 溃疡性结肠炎中西医结合诊疗共识意见（2017年）［J］. 中国中西医结合消化杂志， 2018 ， 26 （ 2 ）： 105 - 111，120 .

D'HAENS G ， SANDBORN W J ， FEAGAN B G ， et al . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis ［J］. Gastroenterology ， 2007 ， 132 （ 2 ）： 763 - 786 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 ： 129 - 134 .

REN W H ， LAI M ， CHEN Y ， et al . Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire （IBDQ） for ulcerative colitis and Crohn's disease ［J］. Inflamm Bowel Dis ， 2007 ， 13 （ 7 ）： 903 - 910 .

许涵，唐文 . 中文版炎症性肠病残疾指数的信效度研究［J］ . 中华炎性肠病杂志， 2020 ， 4 （ 4 ）： 304 - 310 .

赵帅，周正华 . 青赤散保留灌肠治疗左半结肠型溃疡性结肠炎的网络药理学研究［J］. 中国医院用药评价与分析， 2021 ， 21 （ 12 ）： 1425 - 1433 .

赵克学 . 活动期溃疡性结肠炎中西医临床诊治策略体会［J］. 中国中医急症， 2015 ， 24 （ 9 ）： 1568 - 1571 .

胡江涛，王思颖 . 溃疡性结肠炎中医证型与结肠镜象结果分析研究［J］. 山西中医， 2023 ， 39 （ 2 ）： 51 - 53 .

张天涵，沈洪 . 炎症性肠病的中医辨治思路［J］. 中医杂志， 2019 ， 60 （ 14 ）： 1191 - 1193，1236 .

NAEGELI A N ， HUNTER T ， DONG Y ， et al . Full， partial， and modified permutations of the Mayo score： characterizing clinical and patient-reported outcomes in ulcerative colitis patients ［J］. Crohns Colitis 360 ， 2021 ， 3 （ 1 ）： otab007 .

中国炎症性肠病诊疗质量控制评估中心，中华医学会消化病学分会炎症性肠病学组 . 中国溃疡性结肠炎诊治指南（2023年·西安）［J］. 胃肠病学， 2024 ， 29 （ 3 ）： 145 - 173 .

YAN Z X ， LIU Y M ， MA T ， et al . Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis：a meta-analysis of randomized controlled trials ［J］. Complement Ther Clin Pract ， 2021 ， 42 ： 101278 . doi： 10.1016/j.ctcp.2020.101278 http://dx.doi.org/10.1016/j.ctcp.2020.101278 .

于耕，王旭，丁琳，等 . 中药肠道给药治疗溃疡性结肠炎作用机制的研究进展［J］. 南京中医药大学学报， 2025 ， 41 （ 10 ）： 1300 - 1311 .

DAS D ， BANERJEE A ， MANNA K ， et al . Quercetin counteracts monosodium glutamate to mitigate immunosuppression in the thymus and spleen via redox-guided cellular signaling ［J］. Phytomedicine ， 2024 ， 126 ： 155226 . doi： 10.1016/j.phymed.2023.155226 http://dx.doi.org/10.1016/j.phymed.2023.155226 .

WANG X ， XIE X ， LI Y ， et al . Quercetin ameliorates ulcerative colitis by activating aryl hydrocarbon receptor to improve intestinal barrier integrity ［J］. Phytother Res ， 2024 ， 38 （ 1 ）： 253 - 264 .

QU Y ， LI X ， XU F ， et al . Kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhi-biting the LPS-TLR4-NF-κB axis ［J］. Front Immunol ， 2021 ， 12 ： 679897 . doi： 10.3389/fimmu.2021.679897 http://dx.doi.org/10.3389/fimmu.2021.679897 .

XUE L ， JIN X ， JI T ， et al . Luteolin ameliorates DSS-induced colitis in mice via suppressing macrophage activation and chemotaxis ［J］. Int Immunopharmacol ， 2023 ， 124 （ Pt B ）： 110996 .

ZHANG D ， GE F ， JI J ， et al . β-sitosterol alleviates dextran sulfate sodium-induced experimental colitis via inhibition of NLRP3/Caspase-1/GSDMD-mediated pyroptosis ［J］. Front Pharmacol ， 2023 ， 14 ： 12184 77 . doi： 10. 3389/fphar.2023.1218477 http://dx.doi.org/10.3389/fphar.2023.1218477 .

冯思敏，宁可，邵平，等 . β-谷甾醇和豆甾醇对小鼠急性结肠炎的治疗作用研究［J］. 中国粮油学报， 2018 ， 33 （ 12 ）： 80 - 86，94 .

ROGLER G . Chronic ulcerative colitis and colorectal cancer ［J］. Cancer Lett ， 2014 ， 345 （ 2 ）： 235 - 241 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Characteristics of Traditional Chinese Medicine Syndromes and Treatment Rules in Ulcerative Colitis Patients in Jiangsu Province：Based on Real-World Data

Comparative Study on the Effects of Qingchang Wenzhong Decoction （清肠温中方） on the Intestinal Mucus Barrier in Conventional and Pseudo-Germ-Free Model Mice of Acute Ulcerative Colitis

Prevention and Treatment of the Relapse of Ulcerative Colitis Based on the Theory of Damp-Heat Latent Pathogen

Traditional Chinese Medicine Therapy for Active Ulcerative Colitis：A Multicenter Bidirectional Cohort Study

Evaluation of Pulmonary Air-Blood Barrier Damage in Ulcerative Colitis Inflammatory Cancer Transformation Model Mice：Based on the "Lung-Intestine Correlation" Theory

Related Author

ZHANG Mengyuan

SHEN Zhaofeng

SHEN Hong

ZHU Lei

GAO Mingxu

LIU Leilei

LU Lijie

WANG Jiali

Related Institution

Jiangsu Province Hospital of Chinese Medicine/Affiliated Hospital of Nanjing University of Chinese Medicine

Dongfang Hospital，Beijing University of Chinese Medicine

School of Traditional Chinese Medicine，Beijing University of Chinese Medicine

Institute of Spleen and Stomach Diseases，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Kunshan Hospital of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Clinical Efficacy of Shenyu Guanchang Formula （参榆灌肠方） Enema Combined with Oral Mesalazine in the Treatment of Left-Sided Ulcerative Colitis with Large Intestine Damp-Heat Syndrome and Network Pharmacology Research

DOI：10.13288/j.11-2166/r.2026.08.013

摘要

Abstract

关键词

Keywords

references